List of Nouress drug patents

Nouress is owned by Baxter Hlthcare Corp.

Nouress contains Cysteine Hydrochloride.

Nouress has a total of 12 drug patents out of which 0 drug patents have expired.

Nouress was authorised for market use on 13 December, 2019.

Nouress is available in solution;intravenous dosage forms.

Nouress can be used as method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof, method of using l-cysteine in an admixture for treating patients needing parenteral nutrition.

The generics of Nouress are possible to be released after 15 March, 2039.

NOURESS Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583155 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10933089 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10918662 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905713 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10912795 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10653719 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10478453 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10905714 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use
Jan, 2039

(15 years from now)

US10493051 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

US10543186 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

US11045438 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

US10702490 BAXTER HLTHCARE CORP Cysteine composition and injection
Mar, 2039

(15 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 December, 2019

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

NOURESS family patents

17

United States

1

Canada

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in